EUROAPI H1 2025 Financial Overview
EUROAPI has reported its financial performance for the first half of 2025, showcasing resilience despite navigating a challenging market environment. The company recorded net sales of €412.1 million, which reflects an 8.2% decline compared to the previous year. However, when accounting for a one-off impact from H1 2024, the drop in sales appears more manageable at 4%.
Financial Metrics Breakdown
Key financial metrics for H1 2025 include an EBITDA of €5.0 million, contrasting sharply with a negative EBITDA of €(1.4) million in H1 2024. Core EBITDA, which excludes non-recurring costs, reached €39.5 million, resulting in a margin of 9.6%. This is slightly below the previous year's margin of 10.6%, attributed to various operational challenges.
Operational Efficiency and Cost Management
A notable achievement this half-year has been the company's effective control over operating expenses (OPEX), which have tangibly decreased due to stringent cost management measures. The net income improved from €(34.8) million in H1 2024 to €(28.5) million in the current year, indicating a positive trajectory in financial performance.
Growth Investments and Strategic Initiatives
EUROAPI strategically allocated 60% of its capital expenditure in H1 2025 towards growth projects. The company has also signed a significant agreement with the French government, which will provide up to €140 million in public aid for investments associated with the IPCEI Med4Cure project. This support underscores EUROAPI's commitment to advancing innovative healthcare solutions.
Strong Market Position and Product Performance
The API Solutions segment faced a sales downturn primarily due to a stark comparison with last year, where figures were inflated by a one-off stock clearance impact. Notably, sales to Sanofi saw a sharp decrease of 24.4% in H1 2025, emphasizing the importance of diversifying the client base and product portfolio.
Future Outlook and Strategic Roadmap
Looking ahead, EUROAPI maintains its guidance for a full-year core EBITDA margin of 7% to 9% of net sales, with a proactive focus on strengthening the performance in the latter half of the year. The management remains optimistic about bolstered sales driven by improved market conditions for opioids, consistent demand for APIs, and a resurgence in sales for Vitamin B12. The transformative FOCUS-27 plan continues to play a crucial role in shaping future growth prospects.
Summary of H1 2025 Key Figures
Financial highlights for H1 2025 include:
- Net Sales: €412.1 million
- EBITDA: €5.0 million
- Core EBITDA: €39.5 million (9.6% margin)
- Net Income: €(28.5) million
As EUROAPI progresses through 2025, its adherence to financial discipline and strategic execution positioning the company to navigate ongoing market fluctuations successfully.
Frequently Asked Questions
What are EUROAPI's core EBITDA margins for H1 2025?
EUROAPI reported core EBITDA margins of 9.6% for the first half of 2025.
How much did net sales decline for H1 2025?
Net sales for H1 2025 declined by 8.2% compared to the previous year.
What investments did EUROAPI make in H1 2025?
EUROAPI dedicated 60% of its capital expenditure to growth projects during H1 2025.
What is the company's outlook for the rest of 2025?
EUROAPI expects to achieve a core EBITDA margin of 7% to 9% and improve sales performance in the second half of 2025.
What strategic actions has EUROAPI taken recently?
The company successfully completed the divestment of the Haverhill site and signed an agreement for public aid from the French government for the IPCEI Med4Cure project.
